Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Fineline Cube Aug 6, 2026
Company Drug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Fineline Cube Aug 6, 2026
Company Drug

Fosun Pharma’s FCN-159 and FCN-437c Win NMPA Marketing Approvals

Fineline Cube May 30, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the receipt of marketing...

Company Deals

CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals

Fineline Cube May 30, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...

Company Medical Device

Acotec Scientific’s E-Peridge Balloon Catheter Approved by China’s NMPA

Fineline Cube May 30, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Company Drug

Jiangsu Hengrui Secures NMPA Approvals for Trastuzumab Rezetecan, Famitinib and HR20013

Fineline Cube May 30, 2025

China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received separate marketing...

Company Drug

NMPA Approves Mabwell’s 8MW0511 for Febrile Neutropenia Prevention

Fineline Cube May 30, 2025

China’s National Medical Products Administration (NMPA) has approved Mabwell (Shanghai) Bioscience Co., Ltd’s (SHA: 688062)...

Company Drug

Hinova’s Deutenzalutamide Approved for Metastatic Prostate Cancer in China

Fineline Cube May 30, 2025

Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) announced that the New Drug Application (NDA) for...

Company Drug

Sino Biopharmaceutical’s TQB2868 Shows Strong Results in Phase II Pancreatic Cancer Trial

Fineline Cube May 30, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented data from its Phase II clinical trial (TQB2868-ALTN-II-01)...

Company Drug

Hansoh Pharma Gains NMPA Clinical Approvals for HS-10510, HS-10542, and HS-20118

Fineline Cube May 30, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received separate clinical...

Company Drug

Genor Biopharma Gains NMPA Approval for CDK4/6 Inhibitor Lerociclib in China

Fineline Cube May 30, 2025

China’s Genor Biopharma Co., Ltd (HKG: 6998) announced that it has received marketing clearance from...

Company Deals

Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development

Fineline Cube May 30, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...

Company Deals

Danaher Partners with AstraZeneca to Advance Precision Medicine

Fineline Cube May 30, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced a strategic partnership with...

Company Drug

Innovent Biologics Doses First Patient in Phase III Psoriasis Trial for Picankibart

Fineline Cube May 30, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first subject dosing in a Phase III...

Company Drug

GSK Halts PIVOT-PO Trial Early as Tebipenem HBr Meets Efficacy Targets for cUTI

Fineline Cube May 30, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the early termination of the pivotal Phase...

Company Drug

Amoytop Biotech Wins NMPA Approval for Weekly Inpegsomatropin in Pediatric Growth Deficiency

Fineline Cube May 30, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) announced that it has received marketing approval from...

Company Drug

Regend Therapeutics Gains NMPA Approval for Phase I/II Study of REGEND003 in Diabetes-Related CKD

Fineline Cube May 30, 2025

Suzhou-based stem cell therapy specialist Regend Therapeutics announced that it has received approval from China’s...

Company Deals

Ganzhou Hemay Pharma Files for HK IPO with SDIC Securities Sponsorship

Fineline Cube May 30, 2025

China-based Ganzhou Hemay Pharmaceutical Co., Ltd. has filed for an initial public offering (IPO) with...

Company Deals

GeneMind Biosciences Closes RMB 280 Million Series C+ Round to Fuel DNA Sequencer Innovation

Fineline Cube May 29, 2025

Shenzhen-based DNA sequencer specialist GeneMind Biosciences Co., Ltd. has reportedly secured RMB 280 million (USD...

Company Medical Device

Abbott Laboratories Receives FDA Approval for Tendyne TMVR System

Fineline Cube May 29, 2025

US-based medical device giant Abbott Laboratories (NYSE: ABT) announced that it has received marketing approval...

Company Deals

AusperBio Secures $50M in Oversubscribed Series B+ Round to Advance Hepatitis B Therapy

Fineline Cube May 29, 2025

Sino-US liver therapy developer AusperBio announced the successful closing of an oversubscribed Series B+ financing...

Company Drug

BMS Gains European Approval for Opdivo Subcutaneous Formulation

Fineline Cube May 29, 2025

Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to...

Posts pagination

1 … 190 191 192 … 704

Recent updates

  • Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance
  • Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer
  • Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%
  • CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer
  • Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance

Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Company

Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%

Company Drug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.